RBL LLC welcomes James Watson to board of directors
Txylo.com/10312852
Trending...
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- Soil Quench Hydration Sticks Save Irrigation Water
HOUSTON, June 17, 2025 ~ Houston, TX - RBL LLC, a biotech venture creation studio focused on developing groundbreaking medical technologies from Rice University, has announced the addition of James Watson to its board of directors. Watson, an operating partner at Andreessen Horowitz and a seasoned executive in the life sciences industry, brings a wealth of experience in business strategy, corporate development, and venture-backed company building to RBL LLC.
According to Paul Wotton, managing partner at RBL LLC, the appointment of James Watson is a strong endorsement of the company's model and potential. With his extensive background in all stages of biotech innovation, from company formation to valuable partnerships, Watson's insights into market dynamics and ability to drive successful outcomes will be crucial as RBL continues to grow.
Rice professor of bioengineering and managing partner of RBL LLC, Omid Veiseh also expressed his excitement about Watson joining the board. He believes that Watson's ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups.
More on Txylo.com
In response to his appointment, James Watson stated that he was drawn to RBL's innovative approach to company creation and its positive impact on the Houston life sciences community. He praised the studio for its efficient approach in identifying promising technologies with clear clinical applications and establishing focused enterprises to advance them. He also highlighted the strategic positioning of RBL in Houston as a key factor in building successful scientific ventures.
Currently serving as an operating partner on the Bio + Health team at Andreessen Horowitz, Watson leads business and corporate development for the firm's life sciences portfolio. Prior to this role, he held executive positions at several biotech companies including Carmot Therapeutics and Sigilon Therapeutics. At Carmot Therapeutics, he led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that contributed to its $2.7 billion acquisition by Roche. He also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly.
With an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth, Watson brings a strong educational background to the RBL board.
Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and Paul Cherukuri. This accomplished group of leaders with deep expertise in biotech innovation, clinical translation, and venture building will provide strategic guidance to help drive RBL's continued growth and success.
According to Paul Wotton, managing partner at RBL LLC, the appointment of James Watson is a strong endorsement of the company's model and potential. With his extensive background in all stages of biotech innovation, from company formation to valuable partnerships, Watson's insights into market dynamics and ability to drive successful outcomes will be crucial as RBL continues to grow.
Rice professor of bioengineering and managing partner of RBL LLC, Omid Veiseh also expressed his excitement about Watson joining the board. He believes that Watson's ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups.
More on Txylo.com
- MyTCRPlus Releases Complete 10DLC Registration Guide for BigCommerce Stores
- Buying a Home in Austin: 4 Markets Under $450K Have 6 to 7.5 Months of Supply, Says Sarah Maddali
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- Systemores Announces Official iOS App Launch of Family Med Tree: Offline-First Digital Health Binder
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
In response to his appointment, James Watson stated that he was drawn to RBL's innovative approach to company creation and its positive impact on the Houston life sciences community. He praised the studio for its efficient approach in identifying promising technologies with clear clinical applications and establishing focused enterprises to advance them. He also highlighted the strategic positioning of RBL in Houston as a key factor in building successful scientific ventures.
Currently serving as an operating partner on the Bio + Health team at Andreessen Horowitz, Watson leads business and corporate development for the firm's life sciences portfolio. Prior to this role, he held executive positions at several biotech companies including Carmot Therapeutics and Sigilon Therapeutics. At Carmot Therapeutics, he led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that contributed to its $2.7 billion acquisition by Roche. He also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly.
With an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth, Watson brings a strong educational background to the RBL board.
Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and Paul Cherukuri. This accomplished group of leaders with deep expertise in biotech innovation, clinical translation, and venture building will provide strategic guidance to help drive RBL's continued growth and success.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Dallas Founder Drops Compliance App Pricing to Lowest in Its Category, Launches Done-For-You Service
- Jokari Launches Press & Brush™ 2-in-1 Travel Toothbrush With Built-In Toothpaste Dispenser
- Jokari Introduces Air Flow Guard™ to Improve Comfort Around Window Air Conditioners
- Living in Austin Gets $295M for Parks and Libraries: What Movers Should Know, Says Sarah Maddali
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- Fort Worth Agent Brings Direct Life Insurance Guidance to Professionals and Business Owners
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
- Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
- Southern Nut 'N' Tree Announces Retirement Auction After 50 Years in Pecan Equipment Industry
- PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
- Houston Retail | Market Report 2026 Q3
- KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
- Affinius Capital Appoints Michael Jordan as Managing Director of Housing Portfolio Management
- Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
- H Mart Haltom City Coming Soon!
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc